BUZZ-Syros Pharma slumps as blood cancer therapy combo 'unlikely to succeed' in study

Reuters08-13

** Shares of Syros Pharmaceuticals decline ~64% to $1.83 premarket

** Late on Monday, SYRS said that an interim analysis of data from a mid-stage study for its blood cancer therapy showed a low probability of success for the trial

** Co said it plans to stop enrolling patients in the study testing its therapy, tamibarotenein, in combination with AbbVie

and partner Roche's Venclexta and azacitidine in newly diagnosed, unfit patients with a type of acute myeloid leukemia $(AML.UK)$

** AML is a rare and aggressive type of blood cancer that starts in the bone marrow and can spread to other types of the body

** SYRS said patients currently enrolled in the study will have the opportunity to remain part of the trial at the discretion of investigators

** SYRS is also testing the therapy in patients with myelodysplastic syndrome, a group of cancers that occur when the blood-forming cells in the bone marrow become abnormal

** As of last close, SYRS down ~36% YTD

(Reporting by Bhanvi Satija in Bengaluru)

((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment